These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18161210)

  • 1. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study.
    Stegmayr BG; Brännström M; Bucht S; Crougneau V; Dimeny E; Ekspong A; Eriksson M; Granroth B; Gröntoft KC; Hadimeri H; Holmberg B; Ingman B; Isaksson B; Johansson G; Lindberger K; Lundberg L; Mikaelsson L; Olausson E; Persson B; Stenlund H; Wikdahl AM;
    Scand J Urol Nephrol; 2005; 39(6):489-97. PubMed ID: 18161210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
    Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.
    Li W; Fu X; Wang Y; Li X; Yang Z; Wang X; Geng W; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
    Cardiology; 2012; 122(3):195-202. PubMed ID: 22854323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Hahn JY; Kim HJ; Choi YJ; Jo SH; Kim HJ; Lee S; Ahn KJ; Song YB; Choi JH; Choi SH; Choi YJ; Lee KH; Lee SH; Gwon HC
    Am Heart J; 2011 Dec; 162(6):1026-33. PubMed ID: 22137076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
    Holmberg B; Brännström M; Bucht B; Crougneau V; Dimeny E; Ekspong A; Granroth B; Gröntoft KC; Hadimeri H; Ingman B; Isaksson B; Johansson G; Lindberger K; Lundberg L; Mikaelsson L; Olausson E; Persson B; Welin D; Wikdahl AM; Stegmayr BG
    Scand J Urol Nephrol; 2005; 39(6):503-10. PubMed ID: 16303728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
    Zhao SP; Peng DQ; Yu BL; Huo Y;
    Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
    Toso A; Leoncini M; Maioli M; Gallopin M; Tedeschi D; Amato M; Bellandi F
    J Cardiovasc Med (Hagerstown); 2011 May; 12(5):318-21. PubMed ID: 21045713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
    Athyros VG; Karagiannis A; Ganotakis ES; Paletas K; Nicolaou V; Bacharoudis G; Tziomalos K; Alexandrides T; Liberopoulos EN; Mikhailidis DP;
    Curr Med Res Opin; 2011 Aug; 27(8):1659-68. PubMed ID: 21714711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.
    Wanner C; Krane V; März W; Olschewski M; Asmus HG; Krämer W; Kühn KW; Kütemeyer H; Mann JF; Ruf G; Ritz E;
    Kidney Blood Press Res; 2004; 27(4):259-66. PubMed ID: 15316128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
    Jones PH; McKenney JM; Karalis DG; Downey J
    Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
    Patti G; Pasceri V; Colonna G; Miglionico M; Fischetti D; Sardella G; Montinaro A; Di Sciascio G
    J Am Coll Cardiol; 2007 Mar; 49(12):1272-8. PubMed ID: 17394957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.